JP2021088567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021088567A5 JP2021088567A5 JP2021015874A JP2021015874A JP2021088567A5 JP 2021088567 A5 JP2021088567 A5 JP 2021088567A5 JP 2021015874 A JP2021015874 A JP 2021015874A JP 2021015874 A JP2021015874 A JP 2021015874A JP 2021088567 A5 JP2021088567 A5 JP 2021088567A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- sequence
- oligomerization tag
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006384 oligomerization reaction Methods 0.000 claims 10
- 102000037865 fusion proteins Human genes 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 229920002704 polyhistidine Polymers 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 1
- 235000014304 histidine Nutrition 0.000 claims 1
- 150000002411 histidines Chemical class 0.000 claims 1
- 230000003606 oligomerizing effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023012758A JP2023041802A (ja) | 2017-08-10 | 2023-01-31 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543788P | 2017-08-10 | 2017-08-10 | |
| US62/543,788 | 2017-08-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530834A Division JP6833851B2 (ja) | 2017-08-10 | 2018-06-01 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023012758A Division JP2023041802A (ja) | 2017-08-10 | 2023-01-31 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021088567A JP2021088567A (ja) | 2021-06-10 |
| JP2021088567A5 true JP2021088567A5 (enExample) | 2021-07-26 |
| JP7289328B2 JP7289328B2 (ja) | 2023-06-09 |
Family
ID=62846219
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530834A Active JP6833851B2 (ja) | 2017-08-10 | 2018-06-01 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
| JP2021015874A Active JP7289328B2 (ja) | 2017-08-10 | 2021-02-03 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
| JP2023012758A Pending JP2023041802A (ja) | 2017-08-10 | 2023-01-31 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530834A Active JP6833851B2 (ja) | 2017-08-10 | 2018-06-01 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023012758A Pending JP2023041802A (ja) | 2017-08-10 | 2023-01-31 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11708418B2 (enExample) |
| EP (3) | EP3587445B1 (enExample) |
| JP (3) | JP6833851B2 (enExample) |
| KR (2) | KR20240015159A (enExample) |
| CN (2) | CN117820498A (enExample) |
| AR (1) | AR112357A1 (enExample) |
| AU (2) | AU2018313028B2 (enExample) |
| BR (1) | BR112020002636A2 (enExample) |
| CA (1) | CA3070789A1 (enExample) |
| EA (1) | EA202090265A1 (enExample) |
| ES (2) | ES2973864T3 (enExample) |
| HU (1) | HUE065510T2 (enExample) |
| MX (3) | MX2020001489A (enExample) |
| PL (1) | PL3587445T3 (enExample) |
| PT (1) | PT3587445T (enExample) |
| TW (1) | TW201910349A (enExample) |
| UY (1) | UY37757A (enExample) |
| WO (1) | WO2019030581A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112357A1 (es) * | 2017-08-10 | 2019-10-23 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
| TW202000692A (zh) * | 2018-02-20 | 2020-01-01 | 美商格里佛診斷方法股份有限公司 | 包含GpIbα的多肽和組合物、編碼該多肽的核酸及包含該多肽或該核酸的細胞 |
| CN112048019B (zh) * | 2019-06-06 | 2023-05-09 | 鲁南制药集团股份有限公司 | 抗人cd47单克隆抗体 |
| AU2021338773A1 (en) * | 2020-09-10 | 2023-05-25 | Casi Pharmaceuticals, Inc. | Methods of blood screening |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| CN114917413B (zh) * | 2022-06-14 | 2023-04-28 | 健诺维(成都)生物科技有限公司 | 一种负载重组多肽的羊膜及其制备方法 |
| WO2024172419A1 (ko) * | 2023-02-16 | 2024-08-22 | 주식회사 디엔티 | Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물 |
| CN117723749B (zh) * | 2024-02-07 | 2024-06-04 | 南昌大学 | 基于分子粘合剂的动态光散射免疫传感检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6506551B1 (en) * | 1999-10-08 | 2003-01-14 | North Shore - Long Island Jewish Research Institute | CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia |
| AU2001273121A1 (en) * | 2000-06-30 | 2002-01-14 | Pharmacia And Upjohn Company | Recombinant staphylococcus aureus peptide deformylase |
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| SI2511297T1 (sl) * | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| EP3753576A1 (en) * | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CN103897063B (zh) * | 2007-06-01 | 2017-04-12 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| EP2388270A3 (en) * | 2007-10-11 | 2012-04-25 | The Hospital For Sick Children | Modulation of SIRPa - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| WO2010037837A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| SG194399A1 (en) * | 2008-10-01 | 2013-11-29 | Amgen Res Munich Gmbh | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| WO2010083253A2 (en) * | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| US20130029358A1 (en) * | 2010-04-01 | 2013-01-31 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
| SG188328A1 (en) * | 2010-09-03 | 2013-04-30 | Stem Centrx Inc | Novel modulators and methods of use |
| EP2530089A1 (en) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| EP2812443B1 (en) * | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| ES2857900T3 (es) * | 2012-04-27 | 2021-09-29 | Novo Nordisk As | Proteínas de unión a antígeno de ligando CD30 humano |
| SG11201408646VA (en) * | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| US9447193B2 (en) * | 2013-03-24 | 2016-09-20 | Development Center For Biotechnology | Methods for suppressing cancer by inhibition of TMCC3 |
| US9599606B2 (en) * | 2014-06-10 | 2017-03-21 | The Board Of Regents Of The University Of Texas System | ADP-ribose detection reagents |
| KR102252119B1 (ko) * | 2014-06-18 | 2021-05-17 | 앨버트 아인슈타인 컬리지 오브 메디신 | Syntac 폴리펩티드 및 이의 용도 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| WO2016081423A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| EP3263599A4 (en) * | 2015-02-16 | 2018-12-19 | Pharma Foods International Co., Ltd. | Anti-cancer agent and antimetastatic agent using fstl1, and concomitant drug for same |
| US9580477B2 (en) * | 2015-03-16 | 2017-02-28 | The Catholic University Of America | Approach to produce HIV-1 GP140 envelope protein trimers |
| SI3274370T1 (sl) * | 2015-03-23 | 2020-02-28 | Bayer Pharma Aktiengesellschaft | Protitelesa proti CEACAM6 in njihova uporaba |
| CA2989993A1 (en) * | 2015-09-08 | 2017-03-16 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| JP2019503167A (ja) * | 2015-11-10 | 2019-02-07 | ユニバーシティ・メディカル・センター・ハンブルク−エッペンドルフＵｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｈａｍｂｕｒｇ − Ｅｐｐｅｎｄｏｒｆ | Ｃｄ３８に対する抗原結合性ポリペプチド |
| AR112357A1 (es) * | 2017-08-10 | 2019-10-23 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
-
2018
- 2018-06-01 AR ARP180101480 patent/AR112357A1/es unknown
- 2018-06-01 EP EP19184018.0A patent/EP3587445B1/en active Active
- 2018-06-01 ES ES19184018T patent/ES2973864T3/es active Active
- 2018-06-01 PT PT191840180T patent/PT3587445T/pt unknown
- 2018-06-01 US US16/079,068 patent/US11708418B2/en active Active
- 2018-06-01 KR KR1020247002508A patent/KR20240015159A/ko active Pending
- 2018-06-01 EA EA202090265A patent/EA202090265A1/ru unknown
- 2018-06-01 ES ES18738376T patent/ES2911243T3/es active Active
- 2018-06-01 HU HUE19184018A patent/HUE065510T2/hu unknown
- 2018-06-01 MX MX2020001489A patent/MX2020001489A/es unknown
- 2018-06-01 KR KR1020187017279A patent/KR102631281B1/ko active Active
- 2018-06-01 JP JP2018530834A patent/JP6833851B2/ja active Active
- 2018-06-01 WO PCT/IB2018/053939 patent/WO2019030581A1/en not_active Ceased
- 2018-06-01 BR BR112020002636-0A patent/BR112020002636A2/pt unknown
- 2018-06-01 PL PL19184018.0T patent/PL3587445T3/pl unknown
- 2018-06-01 CA CA3070789A patent/CA3070789A1/en active Pending
- 2018-06-01 EP EP23205907.1A patent/EP4296680A3/en not_active Withdrawn
- 2018-06-01 UY UY0001037757A patent/UY37757A/es not_active Application Discontinuation
- 2018-06-01 CN CN202410194213.6A patent/CN117820498A/zh active Pending
- 2018-06-01 EP EP18738376.5A patent/EP3464343B1/en active Active
- 2018-06-01 TW TW107119019A patent/TW201910349A/zh unknown
- 2018-06-01 AU AU2018313028A patent/AU2018313028B2/en active Active
- 2018-06-01 CN CN201880000662.5A patent/CN109790210B/zh active Active
-
2020
- 2020-02-06 MX MX2024005669A patent/MX2024005669A/es unknown
- 2020-02-06 MX MX2024008109A patent/MX2024008109A/es unknown
-
2021
- 2021-02-03 JP JP2021015874A patent/JP7289328B2/ja active Active
-
2023
- 2023-01-31 JP JP2023012758A patent/JP2023041802A/ja active Pending
- 2023-05-19 US US18/320,912 patent/US20240228651A9/en active Pending
- 2023-06-28 AU AU2023204121A patent/AU2023204121A1/en active Pending
- 2023-11-20 US US18/514,624 patent/US20240092929A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021088567A5 (enExample) | ||
| JP2018537087A5 (enExample) | ||
| JP2025063029A5 (enExample) | ||
| CA2738209C (en) | Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation | |
| Cox et al. | Structural and functional characterization of the mumps virus phosphoprotein | |
| CN109311934B (zh) | 能够形成具有模块化氢键网络介导特异性的同型寡聚体的多肽及其设计 | |
| AR044776A1 (es) | Proteinas de fusion analogas glp-1 | |
| JP2019122392A5 (enExample) | ||
| JP2017512063A5 (enExample) | ||
| JPWO2020072821A5 (enExample) | ||
| JP2019506166A5 (enExample) | ||
| JP2016501535A5 (enExample) | ||
| IL309260B1 (en) | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding | |
| JP2016000731A5 (enExample) | ||
| JP2016505251A5 (enExample) | ||
| JP2014503198A5 (enExample) | ||
| CN103214563B (zh) | 一种性能改进的重组金黄色葡萄球菌蛋白a亲和配基及其构建方法 | |
| JP2016508143A5 (enExample) | ||
| CN110036108A (zh) | 一种细菌β-1,3-葡聚糖酶及其编码基因与应用 | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| JP2005523681A5 (enExample) | ||
| JPWO2019233990A5 (enExample) | ||
| JP2015515969A5 (enExample) | ||
| CN103755810B (zh) | 一种长效hiv‐1膜融合抑制剂 | |
| Schwardt et al. | The negative regulator of Borna disease virus polymerase is a non-structural protein |